21383285

Source:http://linkedlifedata.com/resource/pubmed/id/21383285

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0441712, umls-concept:C0920321, umls-concept:C1709518, umls-concept:C1831873
pubmed:issue	10
pubmed:dateCreated	2011-3-31
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00612209
pubmed:abstractText	The hepatocyte growth factor/c-MET axis is implicated in tumor cell proliferation, survival, and angiogenesis. ARQ 197 is an oral, selective, non-adenosine triphosphate competitive c-MET inhibitor. A phase I trial of ARQ 197 was conducted to assess safety, tolerability, and target inhibition, including intratumoral c-MET signaling, apoptosis, and angiogenesis.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/, http://linkedlifedata.com/resource/pubmed/grant/C1060/A10334
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/ARQ 197, http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases, http://linkedlifedata.com/resource/pubmed/chemical/CYP2C19 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Focal Adhesion Kinase 1, http://linkedlifedata.com/resource/pubmed/chemical/MET protein, human, http://linkedlifedata.com/resource/pubmed/chemical/PTK2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-met, http://linkedlifedata.com/resource/pubmed/chemical/Pyrrolidinones, http://linkedlifedata.com/resource/pubmed/chemical/Quinolines, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Growth Factor
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1527-7755
pubmed:author	pubmed-author:BarriusoJorgeJ, pubmed-author:BrunettoAndre TAT, pubmed-author:ChaiFengF, pubmed-author:ClarkJeremyJ, pubmed-author:CollinsDavidD, pubmed-author:FutrealAndrewA, pubmed-author:GarmeyEdwardE, pubmed-author:GermuskaMichaelM, pubmed-author:KayeStan BSB, pubmed-author:LeachMartin OMO, pubmed-author:OlmosDavidD, pubmed-author:PopeLornaL, pubmed-author:RiisnaesRuthR, pubmed-author:SavageRonald ERE, pubmed-author:SchwartzBrianB, pubmed-author:TunariuNinaN, pubmed-author:WaghorneCarolC, pubmed-author:YapTimothy ATA, pubmed-author:de BonoJohann SJS, pubmed-author:deSouzaNandita MNM
pubmed:issnType	Electronic
pubmed:day	1
pubmed:volume	29
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1271-9
pubmed:meshHeading	pubmed-meshheading:21383285-Adolescent, pubmed-meshheading:21383285-Adult, pubmed-meshheading:21383285-Aged, pubmed-meshheading:21383285-Angiogenesis Inhibitors, pubmed-meshheading:21383285-Apoptosis, pubmed-meshheading:21383285-Aryl Hydrocarbon Hydroxylases, pubmed-meshheading:21383285-Biopsy, pubmed-meshheading:21383285-Endothelial Cells, pubmed-meshheading:21383285-England, pubmed-meshheading:21383285-Female, pubmed-meshheading:21383285-Focal Adhesion Kinase 1, pubmed-meshheading:21383285-Humans, pubmed-meshheading:21383285-In Situ Nick-End Labeling, pubmed-meshheading:21383285-Magnetic Resonance Imaging, pubmed-meshheading:21383285-Male, pubmed-meshheading:21383285-Maximum Tolerated Dose, pubmed-meshheading:21383285-Middle Aged, pubmed-meshheading:21383285-Neoplasms, pubmed-meshheading:21383285-Neoplastic Cells, Circulating, pubmed-meshheading:21383285-Neovascularization, Pathologic, pubmed-meshheading:21383285-Phosphorylation, pubmed-meshheading:21383285-Polymorphism, Single Nucleotide, pubmed-meshheading:21383285-Protein Kinase Inhibitors, pubmed-meshheading:21383285-Proto-Oncogene Proteins c-met, pubmed-meshheading:21383285-Pyrrolidinones, pubmed-meshheading:21383285-Quinolines, pubmed-meshheading:21383285-Receptors, Growth Factor, pubmed-meshheading:21383285-Signal Transduction, pubmed-meshheading:21383285-Treatment Outcome, pubmed-meshheading:21383285-Young Adult
pubmed:year	2011
pubmed:articleTitle	Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.
pubmed:affiliation	Royal Marsden National Health Service Foundation Trust, The Institute of Cancer Research, Sutton, Surrey, UK.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I